Bottom line
Is XLV a good fund? The bottom line
XLV is a managed health care sector ETF from SPDR (State Street).
It charges 0.08% — about $8 a year on every $10,000 invested, cheaper than 99% of health care sector funds we track.
It returned +14.5% over one year, +8.1% a year over five years, +9.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $40.6 billion in net assets and 65 holdings, its largest position is Eli Lilly & Co (16.5%) and the top 10 make up 61.5% of the portfolio.
What stands out
- Low cost: cheaper than 99% of health care sector peers
- 5-year return beat 94% of category peers
- Large and established ($40.6 billion)
What to watch
- Concentrated: top 10 holdings are 61.5% of assets
- 12b-1 marketing fee of 0.02% a year
Updated Nov 19, 2026
What XLV invests in
State Street Health Care Select Sector SPDR ETF (the Fund) seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index (the Index).
In seeking to track the performance of the Index, the Fund employs a replication strategy, which means that the Fund typically invests in substantially all of the securities represented in the Index in approximately the same proportions as the Index. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. The Fund will provide shareholders with at least 60 days' notice prior to any material change in this 95% investment policy. In addition, the Fund may invest in cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by SSGA Funds Management, Inc. ( SSGA FM or the Adviser), the investment adviser to the Fund). The Index includes companies that have been identified as Health Care companies by the…
From the fund's prospectus (filed Jan 28, 2026).
XLV performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| XLV | +14.5% | +8.1% | +9.8% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What XLV costs
On a $10,000 investment, XLV's 0.08% expense ratio costs about $8 a year. The prospectus estimates $103 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
XLV top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 16.51% |
| 2 | Johnson & Johnson | 10.64% |
| 3 | AbbVie Inc | 7.74% |
| 4 | UnitedHealth Group Inc | 6.57% |
| 5 | Merck & Co Inc | 5.52% |
| 6 | Amgen Inc | 3.40% |
| 7 | Thermo Fisher Scientific Inc | 3.24% |
| 8 | Abbott Laboratories | 2.75% |
| 9 | Gilead Sciences Inc | 2.73% |
| 10 | Intuitive Surgical Inc | 2.45% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 61.5% of the fund. See all top 25 holdings and asset mix →
Alternatives to XLV
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 98% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 94% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 90% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 62% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 76% | Compare |
| T. Rowe Price | PRHSX T. Rowe Price Health Sciences Fund, Inc. | 0.83% | 80% | Compare |